Medicure Inc. MC-1 Phase II MEND-CABG Data To Be Presented At 2006 Scientific Sessions Of The American Heart Association

WINNIPEG, MANITOBA -- (MARKET WIRE) -- October 30, 2006 -- Medicure Inc. (TSX: MPH)(AMEX: MCU), a cardiovascular focused biopharmaceutical company, today announced that an abstract describing the results from the Phase II MEND-CABG study will be presented at the 2006 Scientific Sessions of the American Heart Association (AHA), which is being held November 12-15, 2006 in Chicago, Illinois. The 901 patients MEND-CABG study was completed in 2006 with the results demonstrating the clinical benefits of MC-1 in reducing cardiovascular events in patients undergoing coronary artery bypass graft (CABG) surgery.

Back to news